List of Excipients in Branded Drug TRISENOX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Cephalon Inc	TRISENOX	arsenic trioxide	63459-600	HYDROCHLORIC ACID
Cephalon Inc	TRISENOX	arsenic trioxide	63459-600	SODIUM HYDROXIDE
Cephalon Inc	TRISENOX	arsenic trioxide	63459-600	WATER
Cephalon LLC	TRISENOX	arsenic trioxide	63459-601	HYDROCHLORIC ACID
Cephalon LLC	TRISENOX	arsenic trioxide	63459-601	SODIUM HYDROXIDE

Trisenox Excipient Strategy and Commercial Opportunities

Last updated: August 8, 2026

Trisenox is an intravenous arsenic trioxide product for acute promyelocytic leukemia. Its commercial formulation is deliberately simple: arsenic trioxide in water for injection, with sodium hydroxide and hydrochloric acid used for pH adjustment. The strongest opportunities are generic supply, ready-to-use presentations, container-closure systems, hospital safety, stability, and differentiated delivery services rather than new active-ingredient exclusivity.

What is the Trisenox formulation and which excipients does it contain?

Trisenox is supplied as a sterile concentrate containing 10 mg of arsenic trioxide in 10 mL, equivalent to 1 mg/mL. The inactive components listed in the U.S. prescribing information are sodium hydroxide and hydrochloric acid. The product is diluted before intravenous administration and does not rely on a complex excipient system.[1]

Formulation attribute	Trisenox specification
Active ingredient	Arsenic trioxide
Strength	1 mg/mL
Presentation	10 mg/10 mL single-dose vial
Route	Intravenous infusion
Primary excipients	Sodium hydroxide; hydrochloric acid
Vehicle	Water for injection
Administration	Diluted intravenous infusion
Preservative	No preservative identified in the U.S. label
Storage	Controlled room-temperature storage under the approved label
Principal formulation issue	pH control, arsenic stability, container compatibility, and safe handling

The formulation’s simplicity limits conventional excipient-led differentiation. There is no obvious opportunity to create a conventional extended-release, oral, or self-administered product by changing the current excipient package alone. The strategic value lies in improving handling, reducing preparation steps, and controlling degradation or extractables.

What excipient strategy is technically relevant for arsenic trioxide?

pH control is the central excipient function

Sodium hydroxide and hydrochloric acid are used to establish the required pH range. This is more than a manufacturing detail. Arsenic trioxide chemistry is sensitive to pH, oxidation state, concentration, and contact with formulation and packaging materials.

A commercial developer should control:

• pH drift during shelf life;
• arsenic trioxide assay and degradation products;
• visible and subvisible particles;
• interaction with elastomeric stoppers;
• adsorption or precipitation after dilution;
• compatibility with infusion bags and administration sets;
• extractables and leachables from primary packaging.

The use of sodium hydroxide and hydrochloric acid is difficult to protect as a standalone formulation invention because both are routine pharmaceutical pH adjusters. Patent value would require a specific relationship among pH, concentration, stability, impurity profile, container system, or clinical performance.

Preservative-free design is commercially advantageous

Arsenic trioxide is administered in oncology settings where dose preparation and aseptic controls are tightly managed. A preservative-free, single-dose vial avoids preservative exposure and reduces questions about preservative compatibility with oncology infusion systems.

The tradeoff is that single-dose packaging increases waste when the prescribed dose does not consume the full vial. A developer could pursue lower-fill vials, premeasured dose presentations, or ready-to-use infusion bags to reduce wastage. Those products would face sterility, stability, and shipping challenges.

Excipient substitution has limited upside

Replacing sodium hydroxide or hydrochloric acid with alternative buffers could create a formulation patent position, but the commercial case is weak unless the substitute improves a measurable product attribute. Potential objectives include:

• improved long-term pH stability;
• reduced precipitation after dilution;
• lower interaction with vial components;
• better compatibility with polymeric infusion bags;
• reduced arsenic adsorption;
• improved stability in a ready-to-use presentation.

A buffer system that increases osmolality, introduces new toxicology concerns, or complicates intravenous compatibility would likely reduce the product’s value. Because arsenic trioxide has a narrow therapeutic index and a highly controlled clinical use environment, unnecessary excipient complexity is a regulatory disadvantage.

What formulations are protected by Trisenox patents?

The commercially relevant protection for Trisenox is more likely to arise from formulation, dosing, treatment-method, manufacturing, or presentation claims than from the basic use of sodium hydroxide and hydrochloric acid.

Active-ingredient protection

Arsenic trioxide is an old chemical entity. The original product’s regulatory and commercial protection therefore did not depend on a modern composition-of-matter patent covering the molecule. Product-specific exclusivity and patents associated with APL treatment regimens have been more important than chemical-entity exclusivity.

Method-of-use protection

Potential method-of-use claims can cover arsenic trioxide for:

• treatment of relapsed or refractory acute promyelocytic leukemia;
• newly diagnosed low- or intermediate-risk APL;
• combination treatment with all-trans retinoic acid;
• defined induction and consolidation schedules;
• patient populations selected by disease risk or molecular characteristics.

These claims may affect litigation strategy but do not necessarily block an ANDA for the same injectable product if the generic applicant uses an approved carve-out for protected indications.

Formulation and manufacturing protection

A valuable formulation patent would need to claim a specific technical result, such as:

• a defined pH and impurity profile;
• improved stability in a specified container;
• reduced arsenic loss during dilution;
• a ready-to-use diluted product with a defined shelf life;
• a particular sterilization or filling process;
• an infusion bag or vial system that reduces leachables;
• a dosing or handling kit that improves occupational safety.

Routine use of water for injection, sodium hydroxide, and hydrochloric acid would generally provide weak standalone patent protection. The stronger claim strategy would combine excipient levels, pH, concentration, stability data, and packaging limitations.

What is the Orange Book status of Trisenox?

Trisenox is a small-molecule injectable drug regulated under an NDA. Generic competition proceeds through the abbreviated new drug application pathway, not the biosimilar pathway.

Regulatory issue	Commercial implication
FDA pathway	NDA for the reference product; ANDA for generics
Biosimilar pathway	Not applicable
Paragraph IV challenge	Relevant only to any currently listed, unexpired Orange Book patent
Use patents	May be addressed through indication carve-outs
Formulation patents	Could create product-specific litigation risk
Reference-product exclusivity	Original exclusivity periods have expired
Current competitive focus	Generic approval, supply reliability, presentation, and hospital contracting

The original FDA approvals occurred in 2000 for relapsed or refractory APL and in 2004 for broader first-line use in combination with tretinoin in selected patients.[2] Those regulatory exclusivity periods have expired. The commercial question is therefore whether any unexpired, listed patents or other enforceable rights remain relevant to a proposed product. For a mature small-molecule injectable, the practical barriers are often manufacturing validation, sterility assurance, quality systems, and reliable supply rather than Orange Book exclusivity.

When did Trisenox lose exclusivity and when can generic entry occur?

Trisenox lost the economic value of its original regulatory exclusivity long ago. Generic entry became possible after the relevant approval and patent barriers expired or were addressed through litigation, settlement, or labeling carve-outs.

The market-entry sequence is:

1. The generic applicant develops a pharmaceutically equivalent arsenic trioxide injection.
2. The applicant submits an ANDA with bioequivalence and product-quality information appropriate for the injectable.
3. Any Orange Book-listed patents are certified under Paragraph I, II, III, or IV.
4. Protected indications may be carved out of the generic label.
5. FDA evaluates sterility, impurities, container closure, manufacturing controls, and labeling.
6. The generic competes primarily through price, supply continuity, and institutional contracts.

Because the product is administered intravenously, a generic applicant must show more than nominal active-ingredient equivalence. The regulatory file must support container compatibility, particulate control, sterility, endotoxin limits, extractables and leachables, and stability after manufacture.

What generic entry risks exist for Trisenox?

Generic entry risk is high at the active-product level because arsenic trioxide injection is an old, simple small-molecule formulation. The risks are lower for differentiated presentations that solve hospital workflow or safety problems.

Product strategy	Generic entry risk	Commercial defense
Same-strength vial with conventional excipients	High	Low-cost manufacturing and supply reliability
Lower-fill vial	High to moderate	Waste reduction and hospital economics
Ready-to-use infusion bag	Moderate	Stability, sterility, and workflow differentiation
Extended in-use stability presentation	Moderate	Validated compatibility and reduced pharmacy labor
Closed-system preparation kit	Moderate	Safety, handling, and institutional protocol integration
Novel buffer system	Moderate	Must demonstrate stability or compatibility advantage
Oral arsenic product	Lower direct substitution risk	Requires new clinical and regulatory development
Combination APL regimen	Depends on claims	Method-of-use and clinical evidence

The most credible near-term opportunity is a ready-to-use or pharmacy-ready product with validated stability and a documented reduction in preparation time. The product would need to justify its premium against generic vial economics.

What commercial opportunities exist for Trisenox excipients and presentations?

Ready-to-use infusion bags

A premixed infusion product could reduce pharmacy compounding and handling of a hazardous oncology drug. Commercial value would come from:

• fewer preparation steps;
• lower compounding labor;
• reduced calculation errors;
• lower exposure during vial transfer;
• reduced product waste;
• predictable administration volumes.

The main development risks are arsenic stability in the bag, oxygen exposure, light sensitivity, adsorption, elastomer compatibility, and shelf-life after terminal sterilization or aseptic filling.

Smaller vial sizes

A smaller vial could reduce discarded drug when patient doses are below the standard 10 mg fill. The opportunity depends on dose distribution across the treatment population and the cost of adding another vial SKU. A 5 mg vial could have value in pediatric, lower-weight, or dose-adjusted populations, but the economics would depend on manufacturing cost and purchasing contracts.

Pharmacy compounding and closed-transfer systems

A kit that combines the vial, transfer device, closed-system adapter, and compatible infusion components could create a stronger commercial proposition than an excipient change alone. The product could be positioned around occupational exposure reduction and standardized preparation.

This strategy may require device clearances, human-factors work, compatibility testing, and hospital procurement adoption. The intellectual-property position would likely involve device and system claims rather than conventional excipient claims.

Stability-enhancing packaging

Arsenic trioxide developers can pursue packaging differentiation through:

• low-extractable elastomers;
• coated glass vials;
• oxygen-reduced headspace;
• light-protective secondary packaging;
• validated polymer infusion bags;
• tamper-evident and hazardous-drug labeling systems.

Packaging claims can be commercially useful if they produce a longer shelf life, lower impurity levels, or a ready-to-use product. They are less valuable if they merely describe routine materials without demonstrated performance.

How strong is the Trisenox patent estate?

The active-ingredient patent estate is weak because arsenic trioxide is an established compound. Product-level patent strength depends on the scope and remaining term of any formulation, manufacturing, dosing, or treatment patents.

Patent category	Likely strength for a new entrant	Strategic assessment
Arsenic trioxide composition of matter	Very low	Old compound
Basic injectable formulation	Low	Routine excipients and vehicle
Defined pH and stability profile	Moderate	Requires robust comparative data
Ready-to-use presentation	Moderate	Stronger if shelf-life and compatibility are novel
Container-closure system	Moderate	Depends on technical performance
APL treatment method	Variable	Can affect labeling and litigation
Manufacturing process	Variable	Strong only if difficult to design around
Closed-system administration device	Moderate to high	Depends on device architecture and claims

A new entrant should not rely on excipient selection alone to establish durable exclusivity. The strongest commercial package would combine a differentiated formulation, proprietary container system, validated handling advantage, and clinical or pharmacoeconomic evidence.

Which companies are competing in the Trisenox market?

The reference product has historically been associated with Cephalon and later Teva. Generic arsenic trioxide products may be supplied by multiple injectable-drug manufacturers, depending on jurisdiction and current FDA approvals.

Competition is shaped by:

• FDA approval status;
• shortage history and manufacturing continuity;
• hospital group purchasing contracts;
• vial fill size;
• wholesale acquisition cost;
• backorder performance;
• quality history;
• availability of ready-to-use products.

Public revenue attribution for Trisenox is limited because the product has been marketed within broader oncology portfolios. Revenue exposure is therefore best assessed through product-level sales disclosures, procurement data, and hospital purchasing information rather than relying on corporate segment revenue.

What litigation and settlement issues affect Trisenox?

Potential litigation can involve:

• Orange Book-listed patents;
• method-of-use claims;
• formulation patents;
• ANDA Paragraph IV certifications;
• patent-term calculations;
• settlement agreements governing generic launch;
• labeling carve-outs;
• manufacturing or supply agreements.

No biosimilar litigation framework applies because Trisenox is a small-molecule drug. A Paragraph IV challenge would matter only if an unexpired listed patent covers the proposed product or an intended use. A generic could still launch with a section viii statement or a carved-out indication if the remaining claims are limited to a protected use.

For commercial planning, the highest-risk legal issues are usually current patent status, settlement-restricted launch dates, and whether a generic’s proposed label omits a patented indication. These issues should be evaluated separately from the technical equivalence of the formulation.

How does Trisenox compare with alternative APL treatments?

Trisenox competes clinically with all-trans retinoic acid-based regimens and chemotherapy-containing protocols. In low- and intermediate-risk APL, arsenic trioxide plus tretinoin has become a major treatment approach. In high-risk disease, treatment may include additional cytoreduction or chemotherapy depending on the clinical setting and guideline framework.[3]

Criterion	Trisenox injection	Oral APL therapy	Conventional chemotherapy
Administration	Intravenous	Oral	Usually intravenous, sometimes oral
Excipient opportunity	Moderate	Higher potential for solid dosage innovation	Depends on product
Preparation burden	High	Lower	Variable
Hazardous handling	Significant	Product-dependent	Often significant
Differentiation route	Ready-to-use, packaging, workflow	Formulation and adherence	Regimen and supportive care
Generic risk	High for simple injection	Variable	Established in many agents

The injectable route creates a stronger business case for pharmacy workflow innovation than for new excipient chemistry.

What is the commercial outlook for Trisenox formulation innovation?

The most attractive opportunities rank as follows:

1. Ready-to-use infusion bags with validated shelf life.
2. Smaller vial fills that reduce waste.
3. Closed-system transfer and administration kits.
4. Packaging that improves arsenic compatibility and reduces extractables.
5. Pharmacy services built around standardized preparation.
6. Novel excipient systems only where they deliver measurable stability or safety benefits.

The commercial ceiling is constrained by mature generic competition, a narrow oncology indication, and the absence of meaningful composition-of-matter exclusivity. A premium product must demonstrate lower total treatment cost, lower preparation risk, or better supply performance.

Key Takeaways

• Trisenox contains arsenic trioxide at 1 mg/mL with sodium hydroxide and hydrochloric acid as the principal listed excipients.
• Excipient substitution alone is unlikely to create a strong commercial moat.
• Ready-to-use bags, smaller vial fills, closed-transfer systems, and improved packaging offer better opportunities.
• Trisenox is a small-molecule product subject to the ANDA pathway, not biosimilar regulation.
• Original regulatory exclusivity has expired, making generic competition the principal market risk.
• Patent value is more likely to arise from defined stability, packaging, manufacturing, dosing, or method-of-use claims.
• The best commercial strategy combines technical differentiation with hospital labor savings and supply reliability.

FAQs

Can arsenic trioxide be reformulated as an oral product?

Yes, but an oral product would require a new formulation, pharmacokinetic program, clinical development, and regulatory strategy. It would compete with a different administration model rather than function as a simple Trisenox generic.

Do Trisenox excipients create a meaningful allergy risk?

The listed excipients are common pH-adjusting agents. The principal clinical risks arise from arsenic trioxide itself, including differentiation syndrome, QT prolongation, electrolyte abnormalities, and other treatment-related toxicities.[1]

Is a ready-to-use Trisenox bag patentable?

It may be patentable if the product has a novel and non-obvious combination of concentration, pH, container, stability period, compatibility, or preparation characteristics. A generic premixed presentation without a technical distinction would face a weaker patent position.

Can a generic Trisenox product omit protected APL uses?

Potentially. A generic applicant may use a labeling carve-out for a patented method of use, subject to FDA requirements and the scope of the relevant patent claims.

What is the highest-value excipient opportunity for arsenic trioxide?

The highest-value opportunity is an excipient or packaging system that materially improves stability in a ready-to-use infusion presentation while maintaining intravenous compatibility, sterility, and a commercially useful shelf life.

References

1. U.S. Food and Drug Administration. (2024). Trisenox (arsenic trioxide) injection: Prescribing information. Teva Pharmaceuticals USA, Inc.

2. U.S. Food and Drug Administration. (2000, 2004). FDA approval history for Trisenox (arsenic trioxide). Drugs@FDA.

3. National Comprehensive Cancer Network. (2024). NCCN clinical practice guidelines in oncology: Acute myeloid leukemia. NCCN.